MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements

Reuters

2025/06/06

MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements

MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the second half of 2025. First quarter 2025 revenues were reported at $78 million, with a non-GAAP net income of $22 million. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541409008"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541409008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541409008?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 02:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541409008","market":"nz","top_or_hot":-1,"title":"MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the second half of 2025. First quarter 2025 revenues were reported at $78 million, with a non-GAAP net income of $22 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 02:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the second half of 2025. First quarter 2025 revenues were reported at $78 million, with a non-GAAP net income of $22 million. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL5SkMqz:1","article_id":"2541409008","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541409008","pubTimestamp":1749149872,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the seco","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗","BK4139":"生物科技"},"translate_title":"MannKind Corporation发布演示文稿，重点介绍Afrezza的增长、强劲的财务状况和管道进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":0.9},"content_text":"MannKind Corporation Unveils Presentation Highlighting Afrezza Growth, Strong Financials, and Pipeline Advancements\n    \n\n        MannKind Corporation recently held a presentation at the Jefferies Global Healthcare Conference, highlighting key aspects of its business performance and future plans. The company reported strong financial health with cash, cash equivalents, and investments totaling $198 million. MannKind's product, Afrezza, demonstrated a 20% growth in new prescriptions compared to the first quarter of 2024, with expectations for a label update by the fourth quarter of 2025. Additionally, the company plans to submit a supplemental Biologics License Application for pediatric indication expansion by mid-2025. The Tyvaso DPI collaboration contributed $30 million in royalty revenue and $29 million in manufacturing-related revenues during the first quarter. MannKind is also making progress in its pipeline, with the Clofazimine Inhalation Suspension on track to meet its interim enrollment target by the end of 2025, and plans to advance the Nintedanib DPI into the next phase of global development in the second half of 2025. First quarter 2025 revenues were reported at $78 million, with a non-GAAP net income of $22 million. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}